Predicting and Testing Helix-Mimetic Inhibitors of the p53-Mdm2 Interaction

Abstract

Aberrant protein-protein interactions (PPIs) are found in many disease states. Consequently, there is a need for PPI inhibitors for use as research tools and pharmaceutical lead compounds. Computational methods could greatly assist with the search for new PPIs. Oligobenzamides are novel PPI inhibitors which can theoretically be produced to display any sequence of side chains. Understanding the nature of oligobenzamide binding is important for identification of the most efficient strategy of predicting oligobenzamide inhibitors. The prediction of oligobenzamide affinities using thermodynamic integration and implicit solvent methods is described. Affinities of oligobenzamides for Mdm2 predicted using implicit solvent methods bore a moderate correlation with measured affinities. Examination of MM-PBSA results using analysis of variance revealed that it is not necessary to run simulations with every member of a large combinatorial library in order to predict their relative affinities because within a particular binding site, the degree of interaction between the side chains is small. However, it could be useful to separate molecules based on their predicted binding pose because oligobenzamides can bind to Mdm2 in many different ways, depending on the choice of side chains. This insight will be valuable for future attempts to predict oligobenzamide affinities. The 1H-15N HSQC NMR spectrum peaks of 15N-labelled Mdm2 L33E were assigned to facilitate the future validation of binding poses. An oligoamide was shown using NMR to bind in the correct place. However, NMR testing revealed that oligobenzamides can aggregate in aqueous solution despite being soluble. A novel FRET-based method was also developed which can be used to test potential inhibitors with a low solubility and high absorbance during their development. It was adapted for a microwell plate to facilitate future high throughput screening and an assay involving Cherry-labelled Mdm2 was tested which could be developed into an in vivo assay in the future

    Similar works